Navigation Links
MichBio Responds to Governor's Plan to Repeal Tort Reform Laws
Date:1/30/2008

ANN ARBOR, Mich., Jan. 30 /PRNewswire-USNewswire/ -- In a letter to Governor Jennifer Granholm today, MichBio Executive Director, Stephen Rapundalo, Ph.D., responded to the Governor's State of the State Address wherein she called for a repeal of current tort laws. MichBio is the statewide association for Michigan's life sciences industry.

"MichBio lauds your efforts, and those of the legislature, to diversify the state's economy by focusing on high technology areas like life sciences," said Rapundalo, writing on behalf of MichBio's more than 230 members. "However, a repeal of existing tort laws would be a detriment to the life sciences industry, would reverse 10 years of steady growth, neuter the economic development impact of the 21st Century Jobs Fund, and without a doubt diminish future investments in this market sector."

Rapundalo indicated that biotechnology and life science companies face many difficult challenges, a risk-averse investor climate, and lengthy and costly research and development timelines.

"Reversing current law would send a strong message that Michigan is not open for business, forcing new and existing biotech companies to look elsewhere to invest. Companies will not pursue their R&D plans with the knowledge or potential for litigation waiting for them at the end of their commercialization pathway. Repeal will result in a loss of current Michigan jobs and discourage any future biotech business investments and job creation in Michigan."

Noting that drugs and medical devices are the most regulated products around, Rapundalo said, "Less than 1/100 of a percent of potential medications investigated survives the FDA regulatory review gauntlet and become product launches. The contention that lay juries with no medical or science training, or understanding of the new drug application process, are better judges of relatively brief testimony, as opposed to the 12-18 month exhaustive review by experts in the field, is irresponsible. The tort system is simply ill-suited to reach a better conclusion than the FDA on drug or medical device safety.

"So let's leave product liability to the experts, and leave the tort system as is. Current law and process present an appropriate balance whereby the FDA is allowed to perform its regulatory duties, but allowing for punishment of companies that willfully withhold information or interfere with the drug approval process. Let's not unduly raise the risks for the many due to failures of the few, where current law and tort reform already provides for meaningful recourse to the injured. Michigan residents are already more than adequately protected."

Rapundalo said the issue of tort reform may be politically expedient, but it is not a benefit in practical terms. "We have made so much progress in Michigan, especially in the face of difficult economic times. I know the state would like to see the growth in the life sciences community continue, but changing these laws could do irreparable harm to all of the progress that we have made. The proposed repeal is simply at odds with our state's economic development strategy at a time when we can least afford further losses in the life sciences industry."

MichBio is committed to driving the growth of Michigan's life science industry and to fostering the collective impact of its members by serving as their unified voice and by providing them with education, information, connections and other services. MichBio members include life sciences companies, academic and research institutions, bioscience service providers, and related organizations.


'/>"/>
SOURCE MichBio
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. MichBio Expo Opens in Lansing Next Week
2. MichBio Announces Student Career Day at Michigan State University
3. MichBio Issues 2007/8 Michigan Life Sciences Directory and Resources Guide
4. MichBio Announces Expo Tours; Extends Deadline for Innovator Showcase Applications
5. Michigan Life Sciences Pipeline to Kick Off MichBio Expo
6. CellCyte Genetics Corp. Responds to Plaintiff Law Firm Press Releases
7. Bio-Identical Hormone Menopause Doctor Responds to Recent FDA News About Estriol
8. Bio-Identical Hormone Menopause Doctor Responds to Outrageous FDA News
9. CryoLife Responds to Inaccurate Assertions from Plaintiffs Attorney
10. GlaxoSmithKline Responds to JAMA Article on the ICES Thiazolidinediones and Cardiovascular Outcomes in Older Patients with Diabetes
11. Michigan Catholic Conference Responds to Formation of Embryonic Stem Cell Research Ballot Committee
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/16/2017)... ... 16, 2017 , ... Appellate Court of New Jersey approved ... filed by India-based Dishman Pharmaceutical & Chemical Ltd. company (DPCL) for its motion ... its Dishman Group’s 100% wholly owned New Jersey-based subsidiary Dishman USA located in ...
(Date:1/16/2017)... , Jan. 16, 2017  Eurofins Genomics today announced ... allow more customers to receive their primers in a ... compromise in quality found with other providers. Express oligos ... States at no additional fee. ... genetic studies, including DNA sequencing, genotyping, site-directed mutagenesis, and ...
(Date:1/13/2017)... 13, 2017 Research and Markets has announced ... - Global Forecast to 2021" report to their offering. ... The biosimilars market ... 3.39 Billion in 2016, at a CAGR of 26.3%. ... product, manufacturing type, and application. Factors such as rising incidence of ...
(Date:1/13/2017)... (PRWEB) , ... January 13, 2017 , ... ... every cuvette-related demand that it has found among its diverse customer base. The ... for use in most brands electroporators including BTX and Bio-Rad. FireflySci is introducing ...
Breaking Biology Technology:
(Date:12/7/2016)... PUNE, India , December 7, 2016 According to ... NLP, Machine Learning), Software Tool (Facial Expression, Voice Recognition), Service, Application Area, End ... size is estimated to grow from USD 6.72 Billion in 2016 to USD ... Continue Reading ... ...
(Date:12/7/2016)... LONDON , Dec. 7, 2016   Avanade ... most successful Formula One teams in history, exploit biometric ... pit stop performance and maintain the competitive edge against ... in 2016. Avanade has worked with ... a range of biometric data (heart rate, breathing rate, ...
(Date:12/6/2016)... , Dec. 6, 2016  Zimmer Biomet Holdings, Inc. ... has priced an offering of €500.0 million principal amount of ... principal amount of its 2.425% senior unsecured notes due 2026. ... to occur on December 13, 2016, subject to the satisfaction of ... annual basis. The Company intends ...
Breaking Biology News(10 mins):